Bruce Linton

Cannabis Stocks Continue Skyrocketing Amid Florida And Global Legalization Advances
Canopy Growth's Consolidation Strategy Following NASDAQ Notice That Shares Are Too Low For Too Long
EXCLUSIVE: Bruce Linton Talks Changing Perceptions Of Cannabis On 'The Raz Report'
Canopy Growth's Consolidation Strategy Following NASDAQ Notice That Shares Are Too Low For Too Long
EXCLUSIVE: Bruce Linton Talks Changing Perceptions Of Cannabis On 'The Raz Report'
How Berner's Weed Brand, Cookies, Preserves Quality Across State Lines: 'A Lot Of Airplanes And A Lot Of Travel'
Will Cannabis Entrepreneurs Switch To Psychedelics?

Bruce Linton Recent News

MindMed Q3 Earnings: Big Improvement, Kicks Off Sleep & Cognitive Study With Dose Low-Dose LSD
MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a biotech company developing psychedelic-inspired therapies, announced its financial results late Monday for the third quarter ended Sept. 30, 2021.
Bruce Linton, Chairman of Gage Cannabis: 'New York One of the Biggest Movers' And Will Soon Prove It
The cannabis market opening up in New York will be a massive catalyst for the industry, according to the sector veteran, Bruce Linton, chairman of Gage Cannabis and former CEO of Canopy Growth (NASDAQ: CGC). 
Gage Growth Posts Q4 Earnings: What Cannabis Stock Investors Need To Know
Vertically integrated cannabis operator Gage Growth Corp. (CSE: GAGE) reported Thursday that it had generated $39.9 million in revenue at a gross margin of 30.8% in fiscal 2020, representing a 1,972% year-over-year increase.
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed. 
Bruce Linton On His $150M Venture: 'Hemp's Disruptive Potential Is Higher Than CBD'
Article written in collaboration with Natán Ponieman.
Gage Cannabis Seeks $50M In Financing Before IPO, Exec Chair Bruce Linton Says
Craft cannabis brand Gage Cannabis Co. is poised to raise up to $50 million through a share offering. The Detroit-based company is launching a Regulation A, Tier 2, equity financing, offering more than 28.5 million shares of subordinate voting shares at $1.75 per share.
Vireo's Revenue Spikes 34% In Cannabis Company's 'Strongest Quarter Of Growth'
Medical cannabis company Vireo Health International Inc. (CNSX: VREO) (OTCQX: VREOF) released first-quarter financial results Tuesday, with revenue of $12.1 million.
Cannabis Vet Bruce Linton Out At Vireo
Cannabis veteran Bruce Linton has left Vireo Health International Inc. (CNSX: VREO) (OTCQX: VREOF) after being at the company for just seven months.
Red Light Holland Lists On CSE, Appoints Bruce Linton As Advisory Chair
Psychedelics company Red Light Holland Corp. expects its common shares to start trading Thursday on the Canadian Securities Exchange under the ticker symbol "TRIP."  
Omura Chief Praises Funding Efforts, Has High Hopes For Rest Of 2020
By Anthony Noto and Javier Hasse.
Bruce Linton Joins $5M Funding Round For CBD Startup Omura
Former Canopy Growth (NYSE: CGC) CEO and founder, Bruce Linton, is now backing Omura.
Vireo Health Raises $10M In Private Offering, Says It's Made Cost Cuts
The Psychedelics Bull Run Has Begun With Publicly-Traded MindMed
MindMed Lists On NEO Exchange, Becomes First Psychedelics Company To Go Public
The Council For Federal Cannabis Regulation Launches, Targets CBD Regulation First
Bruce Linton's 2020 Vision: Free CBD, Cannabis Opportunities In Europe, Legal Psychedelics
Cannabis Execs Tackle Branding, Pot Stock Valuations: 'Dispensaries Are The Brand'
Martha Stewart Will Launch CBD Products For Animals: Here's What You Need To Know
Bruce Linton Talks Psychedelics Investments, Microdosing And LSD: 'The Therapeutic Potential Of Psychedelics Is Greater Than Cannabinoids'
The Keys To Understanding Psilocybin's Medical Value, Market Potential
Vireo Health Trades Down On Q3 Results, CEO Sees 'Clear Path To Profitability'
Exclusive: Canopy Growth's CEO On The Cannabis Company's Stock Price, Growth Potential, Global Footprint